Autopsy report · NCT06487858
A Study of BGB-R046 as Monotherapy and in Combination With Tislelizumab in Solid Tumors
Cause of deathFunding or business
“This decision is due to a company business decision with a strategy change on the BGB-R046 development in Advanced or Metastatic Solid Tumors.”
Life of this trial
- Ran for about 1 year 9 months before it stopped.
- 42 participants enrolled.
- No results are posted on the registry.
Vital statistics
- Status
- Terminated
- Phase
- Phase 1
- Sponsor
- BeOne Medicines
- Sponsor type
- Industry
- Conditions
- Solid Tumor
- Interventions
- BGB-R046; Tislelizumab
- Participants
- 42
- Sites
- 8
- Countries
- China
Trials that died the same way
- A Study of BGB-21447, a Bcl-2 Inhibitor, in Mature B-Cell Malignancies
“This decision is due to a company business decision with strategy change on the BGB-21447 development in B-cell malignancies and is not driven by safety concerns.”
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.